<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2011-0839</journal-id>
<journal-title><![CDATA[Universitas Medica]]></journal-title>
<abbrev-journal-title><![CDATA[Univ. Med.]]></abbrev-journal-title>
<issn>2011-0839</issn>
<publisher>
<publisher-name><![CDATA[Pontificia Universidad Javeriana]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2011-08392018000200037</article-id>
<article-id pub-id-type="doi">10.11144/javeriana.umed59-2.cand</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Opciones terapéuticas frente a especies de Candida resistentes a las equinocandinas]]></article-title>
<article-title xml:lang="en"><![CDATA[Therapeutic Options in the Management of Echinocandin Resistant Candida Species]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cortés Hidalgo]]></surname>
<given-names><![CDATA[Andrea Patricia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Roa Dueñas]]></surname>
<given-names><![CDATA[Oscar Hernando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Méndez Fandiño]]></surname>
<given-names><![CDATA[Yardany Rafael]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez-Moreno]]></surname>
<given-names><![CDATA[Carlos A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Pontificia Universidad Javeriana  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Erasmus Medical Center  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Holanda</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Boyacá  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Erasmus Medical Center  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Holanda</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Universidad Pedagógica y Tecnológica de Colombia  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,Universidad Nacional de Colombia  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af8">
<institution><![CDATA[,Clínica Universitaria Colombia, Colsanitas S. A.  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2018</year>
</pub-date>
<volume>59</volume>
<numero>2</numero>
<fpage>37</fpage>
<lpage>51</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S2011-08392018000200037&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S2011-08392018000200037&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S2011-08392018000200037&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: La infección por levaduras del género Candida representa la causa más común de infecciones fúngicas invasivas. Su alta incidencia y la creciente resistencia frente a los azoles y, recientemente, a las equinocandinas ha generado la necesidad de buscar nuevas alternativas farmacológicas. Esta revisión presenta las principales alternativas farmacológicas en estudio frente a Candida resistente a equinocandinas.  Métodos: Se buscó literatura referente al tema en las bases de datos Bireme, Clinical Key, Embase, Cochrane, Lilacs, Pubmed y Scopus. Se incluyeron 15 artículos en esta revisión.  Resultados: Se exploran diferentes alternativas, incluyendo el aumento de dosis de las equinocandinas, su combinación con otros medicamentos y nuevos compuestos en estudio.  Conclusión: A pesar de que las infecciones por Candida resistente a equinocandinas aún representan un desafío, dos alternativas farmacológicas se presentan como promisorias: la combinación con medicamentos existentes como el diclofenaco y nuevos compuestos que se encuentran actualmente en fase II de estudios clínicos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Candida yeasts infections represent the most common cause of invasive fungal infections. Its high incidence and increasing resistance to azoles and, recently, to echinocandins has generated the need to find new therapeutic options. This review presents the main pharmacological alternatives in research against echinocandins resistant Candida.  Methods: A search was conducted in the databases of Bireme, Clinical Key, Embase, Cochrane, Lilacs, Pubmed and Scopus. 15 articles were included in this review.  Results: Several alternatives are explored, including increased doses of echinocandins, combination with other drugs and new compounds under study.  Conclusion: Although resistant Candida infections still represent a challenge, two pharmacological approaches show promise: The combination with existing medicaments such as diclofenac, and new compounds that are currently in Phase II of clinical trials.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[equinocandinas]]></kwd>
<kwd lng="es"><![CDATA[Candida]]></kwd>
<kwd lng="es"><![CDATA[farmacorresistencia fúngica]]></kwd>
<kwd lng="es"><![CDATA[antifúngicos]]></kwd>
<kwd lng="en"><![CDATA[echinocandins]]></kwd>
<kwd lng="en"><![CDATA[Candida]]></kwd>
<kwd lng="en"><![CDATA[drug resistance]]></kwd>
<kwd lng="en"><![CDATA[fungal]]></kwd>
<kwd lng="en"><![CDATA[antifungal agents]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pappas]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Kauffman]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Andes]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Benjamin]]></surname>
<given-names><![CDATA[D K]]></given-names>
</name>
<name>
<surname><![CDATA[Calandra]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America]]></article-title>
<source><![CDATA[Clin Infect Dis.]]></source>
<year>2009</year>
<volume>48</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>503-35</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pappas]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Rex]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hamill]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Larsen]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Powderly]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A prospective observational study of candidemia: Epidemiology, therapy, influences on mortality in hospitalized adult and pediatric patients]]></article-title>
<source><![CDATA[Clin Infect Dis.]]></source>
<year>2003</year>
<volume>37</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>634-43</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wisplinghoff]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Bischoff]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tallent]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Seifert]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wenzel]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Edmond]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study]]></article-title>
<source><![CDATA[Clin Infect Dis.]]></source>
<year>2004</year>
<volume>39</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>309-17</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wey]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Mori]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pfaller]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Woolson]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Wenzel]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hospital-acquired candidemia: The attributable mortality and excess length of stay]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>1988</year>
<volume>148</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2642-5</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Voss]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Noble]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Verduyn]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Foudraine]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Meis]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Candidemia in intensive care unit patients: Risk factors for mortality]]></article-title>
<source><![CDATA[Infection]]></source>
<year>1997</year>
<volume>25</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>8-11</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glöckner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cornely]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Practical considerations on current guidelines for the management of non-neutropenic adult patients with Candidaemia]]></article-title>
<source><![CDATA[Mycoses]]></source>
<year>2013</year>
<volume>56</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-20</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gudlaugsson]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Gillespie]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Vande Berg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Messer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Herwaldt]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pfaller]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Diekema]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Attributable mortality of nosocomial candidemia, revisited]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2003</year>
<volume>37</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1172-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colombo]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Nucci]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Nouér]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Arthington-Skaggs]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[da Matta]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Warnock]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Morgan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Brazilian Network Candidemia Study. Epidemiology of candidemia in Brazil: A nationwide sentinel surveillance of candidemia in eleven medical centers]]></article-title>
<source><![CDATA[J Clin Microbiol]]></source>
<year>2006</year>
<volume>44</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2816-23</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pittet]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wenzel]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nosocomial bloodstream infections. Secular trends in rates, mortality and contribution to total hospital deaths]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>1995</year>
<volume>155</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1177-84</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nucci]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Queiroz-Telles]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Tobón]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Restrepo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Colombo]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of opportunistic fungal infections in Latin America]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2010</year>
<volume>51</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>561-70</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cortés]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Jaimes]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Leal]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence, prevalence of candidemia in critically ill patients in Colombia]]></article-title>
<source><![CDATA[Rev Chilena Infectol]]></source>
<year>2013</year>
<volume>30</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>599-604</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zaoutis]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Argon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Berlin]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Walsh]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Feudtner]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2005</year>
<volume>41</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1232-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruhnke]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Eigler]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tennagen]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Geiseler]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Engelmann]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Trautmann]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection]]></article-title>
<source><![CDATA[J Clin Microbiol]]></source>
<year>1994</year>
<volume>32</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2092-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beyda]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Garey]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Echinochandin resistance in Candida species: Mechanisms of reduced susceptibility and therapeutic approaches]]></article-title>
<source><![CDATA[Ann Pharmacother]]></source>
<year>2012</year>
<volume>46</volume>
<numero>7-8</numero>
<issue>7-8</issue>
<page-range>1086-96</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="">
<collab>Food and Drug Administration, Center for Drug Evaluation and Research, Division of Special Pathogen and Immunologic Drug Products</collab>
<source><![CDATA[CANCIDASTM for invasive aspergillosis: Background document]]></source>
<year>2001</year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="">
<collab>U. S. Food and Drug Administration</collab>
<source><![CDATA[Drug approval package: Mycamine (Micafungin Sodium) injection]]></source>
<year>2005</year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="">
<collab>U. S. Food and Drug Administration</collab>
<source><![CDATA[Package insert for ERAXIS (anidulafungin) for injection]]></source>
<year>2006</year>
</nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glöckner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Steinbach]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vehreschild]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cornely]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of invasive candidiasis with echinocandins]]></article-title>
<source><![CDATA[Mycoses]]></source>
<year>2009</year>
<volume>52</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>476-86</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vallabhaneni]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kallen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tsay]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus &#8211; United States]]></source>
<year>2016</year>
<publisher-name><![CDATA[MMWR Morb Mortal Wkly Rep]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morales-López]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Parra-Giraldo]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Ceballos-Garzón]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[HP]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez-Moreno]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Invasive infections with multidrug-resistant yeast Candida auris, Colombia]]></article-title>
<source><![CDATA[Emerg Infect Dis.]]></source>
<year>2017</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>162-4</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dimopoulos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Antonopoulou]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Armaganidis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vincent]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How to select an antifungal agent in critically ill patients]]></article-title>
<source><![CDATA[J Crit Care]]></source>
<year>2013</year>
<volume>28</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>717-27</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Denning]]></surname>
<given-names><![CDATA[D. W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Echinocandins: A new class of antifungal]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2002</year>
<volume>49</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>889-91</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castanheira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Woosley]]></surname>
<given-names><![CDATA[LN]]></given-names>
</name>
<name>
<surname><![CDATA[Diekema]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Messer]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
<name>
<surname><![CDATA[Pfaller]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother.]]></source>
<year>2010</year>
<volume>54</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2655-9</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shields]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Press]]></surname>
<given-names><![CDATA[EG]]></given-names>
</name>
<name>
<surname><![CDATA[Updike]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Clancy]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2013</year>
<volume>57</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>3528-35</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pfaller]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Castanheira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lockhart]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Ahlquist]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Messer]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata]]></article-title>
<source><![CDATA[J Clin Microbiol]]></source>
<year>2012</year>
<volume>50</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1199-203</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wiederhold]]></surname>
<given-names><![CDATA[NP]]></given-names>
</name>
<name>
<surname><![CDATA[Najvar]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
<name>
<surname><![CDATA[Bocanegra]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Olivo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Graybill]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2007</year>
<volume>51</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1616-20</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wiederhold]]></surname>
<given-names><![CDATA[NP]]></given-names>
</name>
<name>
<surname><![CDATA[Najvar]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
<name>
<surname><![CDATA[Bocanegra]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Kirkpatrick]]></surname>
<given-names><![CDATA[WR]]></given-names>
</name>
<name>
<surname><![CDATA[Patterson]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2011</year>
<volume>55</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>3254-60</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domán]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kovács]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Perlin]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Kardos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gesztelyi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Juhász]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bozó]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Majoros]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dose escalation studies with caspofungin against Candida glabrata]]></article-title>
<source><![CDATA[J Med Microbiol]]></source>
<year>2015</year>
<volume>64</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>998-1007</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jabra-Rizk]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Shirtliff]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Meiller]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of Farnesol on Candida dubliniensis biofilm formation and fluconazole resistance]]></article-title>
<source><![CDATA[FEMS Yeast Res]]></source>
<year>2006</year>
<volume>6</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1063-73</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hornby]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Lisec]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Tasto]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jahnke]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Shoemaker]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quorum sensing in the dimorphic fungus Candida albicans is mediated by Farnesol]]></article-title>
<source><![CDATA[Appl Environ Microbiol]]></source>
<year>2001</year>
<volume>67</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2982-92</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shirtliff]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Krom]]></surname>
<given-names><![CDATA[BP]]></given-names>
</name>
<name>
<surname><![CDATA[Meijering]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Peters]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Scheper]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Jabra]]></surname>
<given-names><![CDATA[-Rizk MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Farnesol-induced apoptosis in Candida albicans]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2009</year>
<volume>53</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2392-401</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cordeiro]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Teixeira]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Brilhante]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Castelo]]></surname>
<given-names><![CDATA[-Branco DS]]></given-names>
</name>
<name>
<surname><![CDATA[Paiva]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Giffoni Leite]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lima]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Monteiro]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sidrim]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Minimum inhibitory concentrations of amphotericin B, azoles and caspofungin against Candida species are reduced by Farnesol]]></article-title>
<source><![CDATA[Med Mycol]]></source>
<year>2013</year>
<volume>51</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>53-9</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alem]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Douglas]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostaglandins in production during growth of Candida albicans biofilms]]></article-title>
<source><![CDATA[J Med Microbiol.]]></source>
<year>2005</year>
<volume>54</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1001-5</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bink]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kucharíková]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Neirinck]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Vleugels]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Van Dijck]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cammue]]></surname>
<given-names><![CDATA[BP]]></given-names>
</name>
<name>
<surname><![CDATA[Thevissen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The nonsteroidal antiinflammatory drug diclofenac potentiates the in vivo activity of caspofungin against Candida albicans biofilms]]></article-title>
<source><![CDATA[J Infect Dis.]]></source>
<year>2012</year>
<volume>206</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1790-7</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vane]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Botting]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanism of action of nonsteroidal anti-inflammatory drugs]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>1998</year>
<volume>104</volume>
<numero>3A</numero>
<issue>3A</issue>
<page-range>2S-8S</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Noverr]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Phare]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Toews]]></surname>
<given-names><![CDATA[GB]]></given-names>
</name>
<name>
<surname><![CDATA[Coffey]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Huffnagle]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins]]></article-title>
<source><![CDATA[Infect Immun]]></source>
<year>2001</year>
<volume>69</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>2957-63</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Erb-Downward]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Noverr]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characterization of prostaglandin E2 production by Candida albicans]]></article-title>
<source><![CDATA[Infect Immun]]></source>
<year>2007</year>
<volume>75</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>3498-505</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nagappan]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Deresinski]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reviews of anti-infective agents: posaconazole: A broad-spectrum triazole antifungal agent]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2007</year>
<volume>45</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1610-7</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xiao]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Madison]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Chau]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Loebenberg]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Palermo]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[McNicholas]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2004</year>
<volume>48</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>568-74</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chau]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Mendrick]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Sabatelli]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Loebenberg]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[McNicholas]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother.]]></source>
<year>2004</year>
<volume>48</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2124-31</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hof]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A new, broad-spectrum azole antifungal: posaconazole-mechanisms of action and resistance, spectrum of activity]]></article-title>
<source><![CDATA[Mycoses]]></source>
<year>2006</year>
<volume>49</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>2-6</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[YL]]></given-names>
</name>
<name>
<surname><![CDATA[Lehman]]></surname>
<given-names><![CDATA[VN]]></given-names>
</name>
<name>
<surname><![CDATA[Averette]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Perfect]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Heitman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2013</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B43">
<label>43.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sucher]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chahine]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
<name>
<surname><![CDATA[Balcer]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Echinocandins: the newest class of antifungals]]></article-title>
<source><![CDATA[Ann Pharmacother]]></source>
<year>2009</year>
<volume>43</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1647-57</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Munro]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[de Bruijn]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Lenardon]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[McKinnon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gow]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stimulation of chitin synthesis rescues Candida albicans from echinocandins]]></article-title>
<source><![CDATA[PLoS Pathog]]></source>
<year>2008</year>
<volume>4</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B45">
<label>45.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klis]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[De Groot]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hellingwerf]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular organization of the cell wall of Candida albicans]]></article-title>
<source><![CDATA[Med Mycol]]></source>
<year>2001</year>
<volume>39</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Gow]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Munro]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Elevated chitin content reduces the susceptibility of Candida species to caspofungin]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2013</year>
<volume>57</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>146-54</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lenardon]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Munro]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Gow]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chitin synthesis and fungal pathogenesis]]></article-title>
<source><![CDATA[Curr Opin Microbiol]]></source>
<year>2010</year>
<volume>13</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>416-23</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Escobar]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nuevos antimicóticos y su uso en dermatología]]></article-title>
<source><![CDATA[Med Cut Iber Lat Am.]]></source>
<year>2004</year>
<volume>32</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>231-42</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Ruijter]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Van Gennip]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Caron]]></surname>
<given-names><![CDATA[HN]]></given-names>
</name>
<name>
<surname><![CDATA[Kemp]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Van Kuilenburg]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Histone deacetylases (HDACs): Characterization of the classical HDAC family]]></article-title>
<source><![CDATA[Biochem J]]></source>
<year>2003</year>
<volume>370</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>737-49</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
<name>
<surname><![CDATA[Edlind]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2002</year>
<volume>46</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>3532-9</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pfaller]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Rhomberg]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Messer]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Castanheira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species]]></article-title>
<source><![CDATA[Diagn Microbiol Infect Dis]]></source>
<year>2015</year>
<volume>81</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>259-63</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52.</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mirati]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[MethylGene reports results of phase II Trial of MGCD290]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B53">
<label>53.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rusnak]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mertz]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Calcineurin: form and function]]></article-title>
<source><![CDATA[Physiol Rev]]></source>
<year>2000</year>
<volume>80</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1483-521</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In vitro interaction between azoles and cyclosporin A against clinical isolates of Candida albicans determined by the chequerboard method , time-kill curves]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2008</year>
<volume>61</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>577-85</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shinde]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Chauhan]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Raut]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Karuppayil]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sensitization of Candida albicans biofilms to various antifungal drugs by cyclosporine A]]></article-title>
<source><![CDATA[Ann Clin Microbiol Antimicrob]]></source>
<year>2012</year>
<volume>11</volume>
<numero>27</numero>
<issue>27</issue>
</nlm-citation>
</ref>
<ref id="B56">
<label>56.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miyazaki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Horii]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hata]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Watanabe]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Nakamoto]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Shirotori]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Murai]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Inoue]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Matsukura]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Abe]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshimatsu]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Asada]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In vitro activity of E1210, a novel antifungal, against clinically important yeasts, molds]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2011</year>
<volume>55</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>4652-8</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chaffin]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Candida albicans cell wall proteins]]></article-title>
<source><![CDATA[Microbiol Mol Biol Rev.]]></source>
<year>2008</year>
<volume>72</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>495-544</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sheppard]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Yeaman]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Welch]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Phan]]></surname>
<given-names><![CDATA[QT]]></given-names>
</name>
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ibrahim]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Filler]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Waring]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Functional and structural diversity in the Als protein family of Candida albicans]]></article-title>
<source><![CDATA[J Biol Chem]]></source>
<year>2004</year>
<volume>279</volume>
<numero>29</numero>
<issue>29</issue>
<page-range>30480-9</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pfaller]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Hata]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
<name>
<surname><![CDATA[Messer]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Moet]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Castanheira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method]]></article-title>
<source><![CDATA[Diagn Microbiol Infect Dis]]></source>
<year>2011</year>
<volume>71</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>167-70</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wiederhold]]></surname>
<given-names><![CDATA[NP]]></given-names>
</name>
<name>
<surname><![CDATA[Najvar]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
<name>
<surname><![CDATA[Fothergill]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[McCarthy]]></surname>
<given-names><![CDATA[DI]]></given-names>
</name>
<name>
<surname><![CDATA[Bocanegra]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Olivo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kirkpatrick]]></surname>
<given-names><![CDATA[WR]]></given-names>
</name>
<name>
<surname><![CDATA[Everson]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Duncanson]]></surname>
<given-names><![CDATA[FP]]></given-names>
</name>
<name>
<surname><![CDATA[Patterson]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2015</year>
<volume>59</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>690-2</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peláez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cabello]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Platas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Díez]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[González del Val]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Basilio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martán]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species biological activity and taxonomy of the producing organisms]]></article-title>
<source><![CDATA[Syst Appl Microbiol]]></source>
<year>2000</year>
<volume>23</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>333-43</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Onishi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Meinz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Curotto]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dreikorn]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenbach]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Discovery of novel antifungal (1,3)-&#946;-D-glucan synthase inhibitors]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2000</year>
<volume>44</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>368-77</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiménez-Ortigosa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Paderu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Motyl]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Perlin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2014</year>
<volume>58</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1248-51</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pfaller]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Messer]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Motyl]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
<name>
<surname><![CDATA[Castanheira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2013</year>
<volume>68</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>858-63</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Masaphy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A novel echinocandin MIG0310 with anticandida activity from newly isolated Fusarium sp. strain MS-R1]]></article-title>
<source><![CDATA[J Appl Microbiol]]></source>
<year>2014</year>
<volume>116</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1458-64</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Locke]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Almaguer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zuill]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bartizal]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characterization of in vitro resistance development to the novel echinocandin, CD101, in Candida species]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2016</year>
<volume>60</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>6100-7</page-range></nlm-citation>
</ref>
<ref id="B67">
<label>67.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pfaller]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Messer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rhomberg]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Castanheira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin-and azole-resistant isolates]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2016</year>
<volume>71</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2868-73</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Perez]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez-Ortigosa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hough]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Locke]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Ong]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Bartizal]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Perlin]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CD101: a novel long-acting echinocandin]]></article-title>
<source><![CDATA[Cell Microbiol.]]></source>
<year>2016</year>
<volume>18</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1308-16</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ong]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Miesel]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bartizal]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Chien]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<source><![CDATA[Prolonged efficacy following one dose of a novel echinocandin, CD101, in a neutropenic mouse model of disseminated candidiasis]]></source>
<year></year>
<publisher-loc><![CDATA[San Diego ]]></publisher-loc>
<publisher-name><![CDATA[Cidara Therapeutics]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B70">
<label>70.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krishnan]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Polowy]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Bryant]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Vaidya]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Smiths]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Laudeman]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility]]></article-title>
<source><![CDATA[J Antibiot]]></source>
<year>2017</year>
<volume>70</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>130-5</page-range></nlm-citation>
</ref>
<ref id="B71">
<label>71.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castanheira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Messer]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Rhomberg]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
<name>
<surname><![CDATA[Pfaller]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<source><![CDATA[Activity of a novel echinocandin biafungin (CD101) tested against most common Candida and Aspergillus species, including echinocandin-and azole-resistant strains. M-1082 ICAAC]]></source>
<year>2014</year>
<publisher-loc><![CDATA[IA, USA ]]></publisher-loc>
<publisher-name><![CDATA[JMI Laboratories North Liberty]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B72">
<label>72.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nishikawa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yamada]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Shibata]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Uchihashi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hayakawa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Nomura]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Mitsuyama]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uptake of T-2307, a novel arylamidine, in Candida albicans]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2010</year>
<volume>65</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1681-7</page-range></nlm-citation>
</ref>
<ref id="B73">
<label>73.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wiederhold]]></surname>
<given-names><![CDATA[NP]]></given-names>
</name>
<name>
<surname><![CDATA[Najvar]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
<name>
<surname><![CDATA[Fothergill]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Bocanegra]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Olivo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[McCarthy]]></surname>
<given-names><![CDATA[DI]]></given-names>
</name>
<name>
<surname><![CDATA[Kirkpatrick]]></surname>
<given-names><![CDATA[WR]]></given-names>
</name>
<name>
<surname><![CDATA[Fukuda]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Mitsuyama]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Patterson]]></surname>
<given-names><![CDATA[T F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2015</year>
<volume>59</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1341-3</page-range></nlm-citation>
</ref>
<ref id="B74">
<label>74.</label><nlm-citation citation-type="">
<source><![CDATA[T-2307 Antifungal agent Phase 1]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B75">
<label>75.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beyda]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Regen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Garey]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunomodulatory agents as adjunctive therapy for the treatment of resistant Candida species]]></article-title>
<source><![CDATA[Current Fungal Infection Reports]]></source>
<year>2013</year>
<volume>7</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>119-25</page-range></nlm-citation>
</ref>
<ref id="B76">
<label>76.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hübel]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Dale]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Liles]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor and interferon-gamma]]></article-title>
<source><![CDATA[J Infect Dis]]></source>
<year>2002</year>
<volume>185</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1490-501</page-range></nlm-citation>
</ref>
<ref id="B77">
<label>77.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gozalbo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Maneu]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Gil]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of IFN-gamma in immune responses to Candida albicans infections]]></article-title>
<source><![CDATA[Front Biosci]]></source>
<year>2014</year>
<volume>19</volume>
<page-range>1279-90</page-range></nlm-citation>
</ref>
<ref id="B78">
<label>78.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Netea]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Van der Meer]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Van Deuren]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kullberg]]></surname>
<given-names><![CDATA[B. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing?]]></article-title>
<source><![CDATA[Trends Immunol]]></source>
<year>2003</year>
<volume>24</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>254-8</page-range></nlm-citation>
</ref>
<ref id="B79">
<label>79.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Djeu]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Pearson]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Leonard]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Blanchard]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Function associated with IL-2 receptor-beta on human neutrophils: Mechanism of activation of antifungal activity against Candida albicans by IL-2]]></article-title>
<source><![CDATA[J Immunol]]></source>
<year>1993</year>
<volume>150</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>960-70</page-range></nlm-citation>
</ref>
<ref id="B80">
<label>80.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bugli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cacaci]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martini]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Torelli]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Posteraro]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Sanguinetti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Paroni Sterbini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Human monoclonal antibody-based therapy in the treatment of invasive candidiasis]]></article-title>
<source><![CDATA[Clin Dev Immunol.]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B81">
<label>81.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cowen]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Köhler]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zaas]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Schell]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease]]></article-title>
<source><![CDATA[Proc Natl Acad Sci U S A]]></source>
<year>2009</year>
<volume>106</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2818-23</page-range></nlm-citation>
</ref>
<ref id="B82">
<label>82.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karwa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Wargo]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efungumab: a novel agent in the treatment of invasive candidiasis]]></article-title>
<source><![CDATA[Ann Pharmacother]]></source>
<year>2009</year>
<volume>43</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1818-23</page-range></nlm-citation>
</ref>
<ref id="B83">
<label>83.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matthews]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Rigg]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hodgetts]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Carter]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gregory]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Illidge]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Burnie]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2003</year>
<volume>47</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2208-16</page-range></nlm-citation>
</ref>
<ref id="B84">
<label>84.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hodgetts]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nooney]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Akeel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Curry]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Awad]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Matthews]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Burnie]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efungumab and caspofungin: pre-clinical data supporting synergy]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2008</year>
<volume>61</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1132-9</page-range></nlm-citation>
</ref>
<ref id="B85">
<label>85.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cassone]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Casadevall]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent progress in vaccines against fungal diseases]]></article-title>
<source><![CDATA[Curr Opin Microbiol.]]></source>
<year>2012</year>
<volume>15</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>27-33</page-range></nlm-citation>
</ref>
<ref id="B86">
<label>86.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kolls]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Th17 cell based vaccines in mucosal immunity]]></article-title>
<source><![CDATA[Curr Opin Immunol]]></source>
<year>2013</year>
<volume>25</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>373-80</page-range></nlm-citation>
</ref>
<ref id="B87">
<label>87.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spampinato]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Leonardi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents]]></article-title>
<source><![CDATA[Biomed Res Int]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B88">
<label>88.</label><nlm-citation citation-type="">
<source><![CDATA[Cidara Therapeutics. Rezafungin (CD101 IV) overview]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B89">
<label>89.</label><nlm-citation citation-type="">
<collab>SCYNEXIS</collab>
<source><![CDATA[SCYNEXIS, Inc. initiates enrollment of the phase 2 study of SCY-078 in vulvovaginal candidiasis]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Jersey City ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B90">
<label>90.</label><nlm-citation citation-type="">
<source><![CDATA[Adis Insight. MGCD 290: Drug profile]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B91">
<label>91.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nett]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Future directions for anti-biofilm therapeutics targeting Candida]]></article-title>
<source><![CDATA[Expert Rev. Anti Infect Ther.]]></source>
<year>2014</year>
<volume>12</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>375-82</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
